CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Neurology

• Publication date

  2007-08-14

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/01.wnl.0000267428.62582.aa
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers for Alzheimer's disease – Clinical needs and application

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

  2006cited by this paper
• Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders

  2006cited by this paper
• The Role of Biomarkers in Clinical Trials for Alzheimer Disease

  2006cited by this paper
• Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease

  2005cited by this paper
• Safety and Acceptability of the Research Lumbar Puncture

  2005cited by this paper
• Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study

  2005cited by this paper
• Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline

  2005cited by this paper
• Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid.

  2005cited by this paper
• Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

  2004cited by this paper
• Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia

  2004cited by this paper
• Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

  2003cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

  2003cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

  2003cited by this paper
• Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

  2002cited by this paper
• Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231

  2001cited by this paper
• The Halstead-Reitan Neuropsychological Test Battery.

  2000cited by this paper
• Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

  2000cited by this paper
• Apolipoprotein E: far more than a lipid transport protein.

  2000cited by this paper
• Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

  2000cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

  1999cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper
• Memory improvement following induced hyperinsulinemia in Alzheimer's disease.

  1996cited by this paper
• The Wechsler Memory Scale—Revised

  1990cited by this paper
• The Neuropsychology Handbook: Behavioral and Clinical Perspectives

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• The Prevalence and Malignancy of Alzheimer Disease

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer’s Disease

  2025cites this paper
• Metabolomic signatures of cognitive function in a type 2 Diabetes-Enriched cohort

  2025cites this paper
• CSF Extracellular Vesicle Aβ42 and Tau/Aβ42 Ratio Are Associated with Cognitive Impairment in Older People with HIV

  2023cites this paper
• Adipocyte-Derived Small Extracellular Vesicles from Patients with Alzheimer Disease Carry miRNAs Predicted to Target the CREB Signaling Pathway in Neurons

  2023cites this paper
• Can neurocognitive assessment be a lower-cost substitute for biomarkers in predicting progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD)? A narrative review

  2023cites this paper
• CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

  2023cites this paper
• Cerebrospinal Fluid Alzheimer’s Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment

  2023cites this paper
• Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

  2023cites this paper
• CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer’s Disease

  2023cites this paper
• CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort

  2023cites this paper
• Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons

  2022cites this paper
• Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria

  2022cites this paper
• Cognitive trajectories preluding the imminent onset of Alzheimer’s disease dementia in individuals with normal cognition: results from the HELIAD cohort

  2022cites this paper
• Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads

  2022cites this paper
• Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study

  2022cites this paper
• The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease

  2021cites this paper
• Management of the predementia stage of Alzheimer’s disease, complicated with hypoactive delirium

  2021cites this paper
• Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease

  2021cites this paper
• Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis

  2020cites this paper
• p-tau/Aβ42 Ratio Associates with Cognitive Decline in Alzheimer's disease, Mild Cognitive Impairment, and Cognitively Unimpaired Older Adults

  2020cites this paper
• Reducing the Healthcare Burden of Delirium

  2020cites this paper
• Residence Capacity

  2020cites this paper
• Concluding Reflections

  2020cites this paper
• Introductory Comments

  2020cites this paper
• Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts.

  2020cites this paper
• Controlling the Confusion

  2020cites this paper
• Mental Health in Parkinson’s Disease

  2020cites this paper
• Deprivation of Liberty

  2020cites this paper
• A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer’s Disease

  2020cites this paper
• What Can Person-Centred Care in Dementia Learn from the Recovery Movement?

  2020cites this paper
• Index

  2020cites this paper
• The Home Assessment in Old Age Psychiatry

  2020cites this paper
• Palliative Care in Dementia

  2020cites this paper
• Psychosocial Interventions in Dementia

  2020cites this paper
• Understanding the Person with Dementia

  2020cites this paper
• Young-Onset Dementias

  2020cites this paper
• A longitudinal study using latent curve models of groups with mild cognitive impairment and Alzheimer's disease.

  2020cites this paper
• Epidemiology and Mental Health in Old Age

  2020cites this paper
• Vascular Dementia

  2020cites this paper
• Supporting Self-Management in Early Dementia

  2020cites this paper
• Clinical Topics in Old Age Psychiatry

  2020cites this paper
• Protein-conformational diseases in childhood: Naturally-occurring hIAPP amyloid-oligomers and early β-cell damage in obesity and diabetes

  2020cites this paper
• Preface

  2020cites this paper
• Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment

  2020cites this paper
• Biomarkers and the Diagnosis of Preclinical Alzheimer’s Disease

  2020cites this paper
• Drug Misuse in Older People

  2020cites this paper
• Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology

  2019cites this paper
• Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease

  2019cites this paper
• Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance.

  2019cites this paper
• Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis

  2019cites this paper
• When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

  2019cites this paper
• Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits.

  2019cites this paper
• A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging

  2019cites this paper
• Mental Health Laws from All UK Jurisdictions

  2019cites this paper
• Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

  2018cites this paper
• The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

  2018cites this paper
• CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau

  2018cites this paper
• Current state of Alzheimer’s fluid biomarkers

  2018cites this paper
• Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies

  2018cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2018cites this paper
• Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer’s disease

  2018cites this paper
• Biomarkers and the diagnosis of preclinical dementia

  2018cites this paper
• Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease

  2018influential citation
• Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults

  2017cites this paper
• Amyloid pathology in the progression to mild cognitive impairment.

  2017cites this paper
• Evaluation of MoCA Scale Ratings with Cognitive Level Correlation in Mild Cognitive Disorders

  2017cites this paper
• Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review

  2017cites this paper
• Cognitive Trajectory Changes Over 20 Years Before Dementia Diagnosis: A Large Cohort Study

  2017cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Correlate With Electroencephalography Parameters Assessed by Exact Low-Resolution Electromagnetic Tomography (eLORETA)

  2017cites this paper
• The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old

  2017cites this paper
• Mood changes in cognitively normal older adults are linked to Alzheimer’s disease biomarker levels

  2016cites this paper
• The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis: The Italian Selfie

  2016cites this paper
• Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment

  2016cites this paper
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016cites this paper
• Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience

  2016cites this paper
• Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases

  2016cites this paper
• Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer’s Disease and Amnestic Mild Cognitive Impairment

  2016cites this paper
• Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.

  2016cites this paper
• Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice

  2016cites this paper
• Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia

  2016cites this paper
• Alcohol misuse in older people

  2016cites this paper
• Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

  2015cites this paper
• Brain aerobic glycolysis functions and Alzheimer’s disease

  2015cites this paper
• Alzheimer’s Disease and Other Neurodegenerative Disorders

  2015cites this paper
• Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD

  2015cites this paper
• Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline

  2015cites this paper
• Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis

  2015cites this paper
• Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

  2015cites this paper
• The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events

  2015cites this paper
• Nouveau procédé permettant la détection de peptides pglu-abêta

  2015cites this paper
• Extracellular RNAs: development as biomarkers of human disease

  2015cites this paper
• Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

  2015cites this paper
• Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study

  2015cites this paper
• Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

  2015cites this paper
• Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

  2015cites this paper
• Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age

  2015cites this paper
• Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

  2015cites this paper
• Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

  2015cites this paper
• Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus

  2015cites this paper
• Modeling the Early Identification and Intervention of Alzheimer’s Disease

  2015cites this paper